Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment


Cite item

Full Text

Abstract

This article discusses recent advances in understanding genetic basis and classification of hypertrophic cardiomyopathy. Here, we review pharmacologic treatment strategies and new developments in disease - specific management of HCM.

About the authors

A Ya Gudkova

Pavlov Medical University; Almazov Federal Medical Research Centre

Email: alexagood-1954@mail.ru
д.м.н., зав. лаб. кардиомиопатий Института сердечно-сосудистых заболеваний ФГБОУ ВО «ПСПбГМУ им. акад. И.П. Павлова», проф. каф. факультетской терапии ФГБОУ ВПО «ПСПбГМУ им. акад. И.П. Павлова»; в.н.с. Института молекулярной биологии и генетики ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава России; ORCID: 0000-0003-0156-8821 St. Petersburg, Russia

A A Streltsova

Almazov Federal Medical Research Centre

врач ультразвуковой диагностики ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава России St. Petersburg, Russia

A A Kostareva

Pavlov Medical University; Almazov Federal Medical Research Centre

к.м.н., директор Института молекулярной биологии и генетики ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава России; ORCID: 0000-0002-9349-6257 St. Petersburg, Russia

References

  1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, Mc Kenna W.J, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart J. 2008;29(2):270-6. doi: 10.1093/eurheartj/ehm 342
  2. Biology Interdisciplinary Working Maron B.J, Towbin J.A, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss A.J, Seidman C.E, Young J.B; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-16. doi: 10.1161/CIRCULATIONAHA.106.1742877
  3. Maron B.J. The 2006 American Heart Association classification of cardiomyopathies is the gold standard. Circulation: Heart Failure. 2008;1(1):72-76. doi: 10.1161/CIRCHEARTFAILURE.108.770826
  4. Arbustini E, Narula N, Dec G.W, Reddy K.S, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi W.A, Bonow R, Tavazzi L, Fuster V, Narula J. The MOGE(S) classification for a phenotype - genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J American College of Cardiology. 2013;62(22):2046-72. doi: 10.1016/j.jacc.2013.08.1644
  5. Denoix P.F. Nomеnclature des cancers. Bull Inst Nat Hyg (Paris). 1944:69-73.
  6. James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. TNM Classification of Malignant Tumours. Eighth edition. Union for International Cancer Control. 2017
  7. Agarwal A, Yousefzai R, Jan M.F, Cho C, Shetabi K, Bush M, Khandheria B.K, Paterick T.E, Treiber S, Sra J, Werner P, Allaqaband S, Bajwa T, Tajik A.J. Clinical application of WHF-MOGE(S) classification for hypertrophic cardiomyopathy. Global Heart. 2015;10(3):209-19. doi: 10.1016/j.gheart. 2015.01.001
  8. Authors/Task Force members, Elliott P.M, Anastasakis A, Borger M.A, Borggrefe M, Cecchi F, Charron P, Hagege A.A, Lafont A, Limongelli G, Mahrholdt H, Mc Kenna W.J, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper P.G, Pieske B, Rapezzi C, Rutten F.H, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu 284
  9. Semsarian C, Ingles J, Maron M.S, Maron B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am College of Cardiology. 2015;65(12):1249-54. doi: 10.1016/j.jacc.2015.01. 019
  10. Lopes L.R, Rahman M.S, Elliott P.M. A systematic review and meta - analysis of genotype - phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99(24):1800-11. doi: 10.1136/heartjnl-2013-303939
  11. Marian A.J, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research. 2017;121(7):749-70. doi: 10.1161/CIRCRESAHA.117.311059
  12. Wang P, Zou Y, Fu C, Zhou X, Hui R. MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Biochemical and Biophysical Research Communications. 2005;329(2):796-9. doi: 10.1016/j.bbrc.2005.02.004
  13. Marian A.J. Modifier genes for hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2002;17(3):242-52. doi: 10.1097/00001573-200 205000-00006
  14. Brugada R, Kelsey W, Lechin M, Zhao G, Yu Q.T, Zoghbi W, Quinones M, Elstein E, Omran A, Rakowski H, Wigle D, Liew C.C, Sole M, Roberts R, Marian A.J. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investigative Medicine. 1997;45(9):542-51.
  15. Arad M, Seidman J.G, Seidman C.E. Phenotypic diversity in hypertrophic cardiomyopathy. Human Molecular Genetics. 2002;11(20):2499-506. doi: 10.1093/hmg/11.20.2499
  16. Dimitrow P.P, Czarnecka D, Jaszcz K.K, Dubiel J.S. Sex differences in age at onset of symptoms in patients with hypertrophic cardiomyopathy. J Cardiovascular Risk. 1997;4(1):33-5. doi: 10.1097/00043798-199702000-00006
  17. Lin C.L, Chiang C.W, Shaw C.K, Chu P.H, Chang C.J, Ko Y.L. Gender differences in the presentation of adult obstructive hypertrophic cardiomyopathy with resting gradient: a study of 122 patients. Japanese Circulation J. 1999;63(11):859-64. doi: 10.1253/jcj.63.859
  18. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, Matsumura Y, Yabe T, Doi Y.L. Gender - specific differences in the clinical features of hypertrophic cardiomyopathy in a community - based Japanese population: results from Kochi RYOMA study. J Cardiology. 2010;56(3):314-9. doi: 10.1016/j.jjcc.2010.07.004
  19. Полякова А.А., Гудкова А.Я., Крутиков А.Н., Семернин Е.Н., Козленок А.В., Пыко С.А., Костарева А.А., Шляхто Е.Н. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD. Артериальная гипертензия. 2018;24(1):29-40. doi: 10.18705/1607-419X-2018-24-1-29-40
  20. Ingles J, Burns C, Bagnall R.D, Lam L, Yeates L, Sarina T, Puranik R, Briffa T, Atherton J.J, Driscoll T, Semsarian C. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. Circulation. Cardiovascular Genetics. 2017;10(2). doi: 10.1161/CIRC GENETICS.116.001620
  21. Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity? Circulation. Cardiovascular Genetics. 2009;2(2):182-90. doi: 10.1161/CIRCGENETICS.108.836478
  22. Girolami F, Ho C.Y, Semsarian C, Baldi M, Will M.L, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman M.J, Olivotto I. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am College of Cardiology. 2010;55(14):1444-53. doi: 10.1016/j.jacc.2009.11.062
  23. Maron B.J, Rowin E.J, Casey S.A, Haas T.S, Chan R.H, Udelson J.E, Garberich R.F, Lesser J.R, Appelbaum E, Manning W.J, Maron M.S. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥ 60 years of age. Circulation. 2013;127(5):585-93. doi: 10.1161/CIRCULATIONAHA. 112.136085
  24. Агеев Ф.Т, Габрусенко С.А, Постнов А.Ю, Акчурин Р.С, Смирнова М.Д, Карпов Р.С, Шапошник И.И, Лопатин Ю.М, Барбараш О.Л, Галявич А.С. Клинические рекомендации по диагностике и лечению кардиомиопатий (гипертрофическая). Кардиологический вестник. 2016;1:3-22.
  25. Philipson D.J, De Pasquale E.C, Yang E.H, Baas A.S. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy. Heart Failure Reviews. 2017;22(6):879-88. doi: 10.1007/s10741-017-9648-x
  26. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt J.P, Mc Connell B.K, Reiken S, Mende U, Marks A.R, Kass D.A, Seidman C.E, Seidman J.G. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clinical Investigation. 2002;109(8):1013-20. doi: 10.1172/JCI200214677
  27. Ho C.Y, Lakdawala N.K, Cirino A.L, Lipshultz S.E, Sparks E, Abbasi S.A, Kwong R.Y, Antman E.M, Semsarian C, González A, López B, Diez J, Orav E.J, Colan S.D, Seidman C.E. Diltiazem treatment for pre - clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC: Heart Failure. 2015;3(2):180-8. doi: 10.1016/j.jchf.2014.08.003
  28. Cooper R.M, Raphael C.E, Liebregts M, Anavekar N.S, Veselka J. New Developments in Hypertrophic Cardiomyopathy. Canadian J Cardiology. 2017;33(10):1254-65. doi: 10.1016/j.cjca.2017.07.007
  29. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Yacoub M, Olivotto I, Belardinelli L, Poggesi C, Cerbai E, Mugelli A. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127(5):575-84. doi: 10.1161/CIRCULATIONAHA.112. 134932
  30. Lovelock J.D, Monasky M.M, Jeong E.M, Lardin H.A, Liu H, Patel B.G, Taglieri D.M, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro R.J, Dudley S.C. Jr. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circulation Research. 2012;110(6):841-50. doi: 10.1161/CIRCRESAHA.111.258251
  31. Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner J.M, Laurino A, Santini L, Bargelli V, Rotellini M, Bartolucci G, Crocini C, Sacconi L, Tesi C, Belardinelli L, Tardiff J, Mugelli A, Olivotto I, Cerbai E, Poggesi C. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. Circulation Heart Failure. 2017;10(3). doi: 10.1161/CIRCHEARTFAILURE.116.003565
  32. Flenner F, Friedrich F.W, Ungeheuer N , Christ T, Geertz B, Reischmann S, Wagner S, Stathopoulou K, Söhren K.D, Weinberger F, Schwedhelm E, Cuello F, Maier L.S, Eschenhagen T, Carrier L. Ranolazine antagonizes catecholamine - induced dysfunction in isolated cardiomyocytes, but lacks long - term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. Cardiovascular Research. 2016;109(1):90-102. doi: 10. 1093/cvr/cvv247
  33. Gentry J.L, 3rd, Mentz R.J, Hurdle M, Wang A. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). J Am College of Cardiology. 2016;68(16):1815-7. doi: 10.1016/j.jacc. 2016.07.758
  34. Olivotto I, Camici P.G, Merlini P.A, Rapezzi C, Patten M, Climent V, Sinagra G, Tomberli B, Marin F, Ehlermann P, Maier L.S, Fornaro A, Jacobshagen C, Ganau A, Moretti L, Hernandez Madrid A, Coppini R, Reggiardo G, Poggesi C, Fattiroli F, Belardinelli L, Gensini G, Mugelli A. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. Circulation Heart Failure. 2018;11:e004124. doi: 10.1161/CIRCHEARTFAILURE.117.004124
  35. Gilead Sciences (2014). Effect of eleclazine (GS-6615) on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM). US National Library of Medicine. https://clinicaltrials.gov/ct2/show/ NCT02291237
  36. Green E.M, Wakimoto H, Anderson, Evanchik M.J, Gorham J.M, Harrison B.C, Henze M, Kawas R, Oslob J.D, Rodriguez H.M, Song Y, Wan W, Leinwand L.A, Spudich J.A, Mc Dowell R.S, Seidman J.G, Seidman C.E. A small - molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617-21. doi: 10.1126/ science.aad3456
  37. Stern J.A, Markova S, Ueda Y, Kim J.B, Pascoe P.J, Evanchik M.J, Green E.M, Harris S.P. A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PloS One. 2016;11(12):e0168407. doi: 10.1371/journal. pone.0168407
  38. Myo-Kardia Inc. (2016). A Phase 2 Open - label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (PIONEER-HCM). US National Library of Medicine. https://clinicaltrials.gov/ct2/show/study/NCT02842242
  39. Crilley J.G, Boehm E.A, Blair E, Rajagopalan B, Blamire A.M, Styles P, Mc Kenna W.J, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am College of Cardiology. 2003;41(10):1776-82. doi: 10.1016/S0735-1097(02)03009-7
  40. Wilder T, Ryba D.M, Wieczorek D.F, Wolska B.M, Solaro R.J. N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am J Physiology. Heart and Circulatory Physiology. 2015;309(10):H1720-30. doi: 10.1152/ajpheart.00 339.2015
  41. Lombardi R, Rodriguez G, Chen S.N, Ripplinger C.M, Li W, Chen J, Willerson J.T, Betocchi S, Wickline S.A, Efimov I.R, Marian A.J. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol - sensitive mechanisms. Circulation. 2009;119(10):1398-407. doi: 10.11 61/CIRCULATIONAHA.108.790501
  42. Marian A.J. The University of Texas Health Science Centre, Houston (2012). Hypertrophic regression with N-Acetylcysteine in HCM (HALT). US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT 01537926
  43. Abozguia K, Elliott P, Mc Kenna W, Phan T.T, Nallur-Shivu G, Ahmed I, Maher A.R, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562-9. doi: 10.1161/CIRCU LATIONAHA.109.934059
  44. Heart Metabolics Limited (2015). Efficacy, safety, and tolerability of perhexiline in subjects with hypertrophic cardiomyopathy and heart failure. US National Library of Medicine. https://clinicaltrials.gov/ct2/show/ NCT02431221
  45. Lim D.S, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103(6):789-92. doi: 10.1161/01.cir.103.6.789
  46. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, Nayor M, Konno T, Gorham J.M, Wolf C.M, Kim J.B, Schmitt J.P, Molkentin J.D, Norris R.A, Tager A.M, Hoffman S.R, Markwald R.R, Seidman C.E, Seidman J.G. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non - myocyte proliferation and requires TGF-β. J Clinical Investigation. 2010;120(10):3520-9. doi: 10.1172/JCI42028DS1
  47. Yamazaki T, Suzuki J-I, Shimamoto R, Tsuji T, Ohmoto-Sekine Y, Ohtomo K, Nagai R. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. International Heart J. 2007;48(6):715-24. doi: 10.1536/ihj.48.715
  48. Penicka M, Gregor P, Kerekes R, et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Molecular Diagnostics. 2009;11(1):35-41. doi: 10.2353/jmoldx.2009.080082
  49. Axelsson A, Iversen K, Vejlstrup N, Ho C.Y, Havndrup O, Kofoed K.F, Norsk J, Jensen M, Bundgaard H. Functional effects of losartan in hypertrophic cardiomyopathy - a randomised clinical trial. Heart. 2016;102(4):285-91. doi: 10.1136/heartjnl-2015-308343
  50. Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, Ahtarovski K, Corell P, Havndrup O, Jensen M, Bundgaard H. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double - blind, placebo - controlled trial. Lancet Diabetes and Endocrinology. 2015;3(2):123-31. doi: 10.1016/S2213-8587 (14)70241-4
  51. New England Research Institutes (2013). Valsartan for attenuating desease evolution in early sarcomeric HCM (VANISH). US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT01912534
  52. Fang L, Ellims A.H, Moore X.L, White D.A, Taylor A.J, Chin-Dusting J, Dart A.M. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Translational Medicine. 2015;13:314. doi: 10.1186/s12967-015-0672-0
  53. Kim J.O, Song D.W, Kwon E.J, Hong S.E, Song H.K, Min C.K, Kim D.H. MiR-185 plays an anti - hypertrophic role in the heart via multiple targets in the calcium - signaling pathways. PLoS One. 2015;10(3):e0122509. doi: 10.1371/ journal.pone.0122509
  54. Wei L, Yuan M, Zhou R, Bai Q, Zhang W, Zhang M, Huang Y, Shi L. MicroRNA-101 inhibits rat cardiac hypertrophy by targeting Rab1a. J Cardiovascular Pharmacology. 2015;65(4):357-63. doi: 10.1097/FJC.000 0000000000203

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies